No pain data yet from Vertex, and sky high deal expectations at JPM 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Greetings from JPM Week 2024! We’re coming to you live from San Francisco, where the industry’s biggest annual convocation is about to kick off — this time, without any substantive chatter about relocation to warmer, drier climes. And why would we leave SF? That yellow orb you see in the sky? It’s the sun! Our morning newsletter has switched to an afternoon format so that our team of STAT reporters on the ground — Allison DeAngelis, Damian Garde, Adam Feuerstein, Matthew Herper, Tara Bannow, Mohana Ravindranath, and Angus Chen — can bring you all the news, analysis, and cocktail party gossip. Let’s do this!

Expectations for M&A are sky high

That’s what happens when the last five weeks of 2023 delivered nearly $40 billion worth of biotech takeouts — RayzeBio, Gracell, Karuna Therapeutics, Icosavax, Cerevel Therapeutics and Immunogen. Folks want more!

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In